Liquid biopsies for detection, surveillance, and prognosis of urothelial cancer: a future standard?

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–386. doi: 10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Faltas BM, Prandi D, Tagawa ST, et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet. 2016;48:1490–1499. doi: 10.1038/ng.3692
   PubMed Web of Science ®Google Scholar
• Vlachostergios PJ, Faltas BM. Treatment resistance in urothelial carcinoma: an evolutionary perspective. Nat Rev Clin Oncol. 2018;15:495–509. doi: 10.1038/s41571-018-0026-y
   PubMed Web of Science ®Google Scholar
• Panebianco V, Narumi Y, Altun E, et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol. 2018;74:294–306. doi: 10.1016/j.eururo.2018.04.029
   PubMed Web of Science ®Google Scholar
• Bagheri MH, Ahlman MA, Lindenberg L, et al. Advances in medical imaging for the diagnosis and management of common genitourinary cancers. Urol Oncol. 2017;35:473–491. doi: 10.1016/j.urolonc.2017.04.014
   PubMed Web of Science ®Google Scholar
• Duquesne I, Weisbach L, Aziz A, et al. Urology on behalf of the YAUUCG of the EA of. The contemporary role and impact of urine-based biomarkers in bladder cancer. Transl Androl Urol. 2017;6(6):1031. doi: 10.21037/tau.2017.11.29
   PubMed Web of Science ®Google Scholar
• Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–548. doi: 10.1038/nrclinonc.2017.14
   PubMed Web of Science ®Google Scholar
• Alfred Witjes J, Lebret T, Compérat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71:462–475. doi: 10.1016/j.eururo.2016.06.020
   PubMed Web of Science ®Google Scholar
• Bardelli A, Pantel K. Liquid biopsies, what we do not know (yet). Cancer Cell. 2017;31:172–179. doi: 10.1016/j.ccell.2017.01.002
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–1012. doi: 10.1016/j.jclinepi.2009.06.005.
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. doi: 10.1136/bmj.c332.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Modak J, Kopetz S, et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol. 2013;31:17–22. doi: 10.1200/JCO.2012.43.1718
   PubMed Web of Science ®Google Scholar
• Lu T, Li J. Clinical applications of urinary cell-free DNA in cancer: current insights and promising future. Am J Cancer Res. 2017;7:2318–2332.
   PubMed Web of Science ®Google Scholar
• Msaouel P, Koutsilieris M. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer. 2011;11:336. doi: 10.1186/1471-2407-11-336
   PubMed Web of Science ®Google Scholar
• Retz M, Lehmann J, Röder C, et al. Cytokeratin-20 reverse-transcriptase polymerase chain reaction as a new tool for the detection of circulating tumor cells in peripheral blood and bone marrow of bladder cancer patients. Eur Urol. 2001;39:507–515. discussion 516-517. doi: 10.1159/000052496.
   PubMed Web of Science ®Google Scholar
• Wegelin O, Bartels DWM, Tromp E, et al. The effects of instrumentation on urine cytology and CK-20 analysis for the detection of bladder cancer. Urology. 2015;86:772–776. doi: 10.1016/j.urology.2015.06.035
   PubMed Web of Science ®Google Scholar
• Melissourgos ND, Kastrinakis NG, Skolarikos A, et al. Cytokeratin-20 immunocytology in voided urine exhibits greater sensitivity and reliability than standard cytology in the diagnosis of transitional cell carcinoma of the bladder. Urology. 2005;66:536–541. doi: 10.1016/j.urology.2005.04.022
   PubMed Web of Science ®Google Scholar
• Golijanin D, Shapiro A, Pode D. Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer. J Urol. 2000;164:1922–1925. doi: 10.1016/S0022-5347(05)66919-4
   PubMed Web of Science ®Google Scholar
• Bhatia A, Dey P, Kumar Y, et al. Expression of cytokeratin 20 in urine cytology smears: a potential marker for the detection of urothelial carcinoma. Cytopathology. 2007;18:84–86. doi: 10.1111/j.1365-2303.2006.00432.x
   PubMed Web of Science ®Google Scholar
• Osman I, Kang M, Lee A, et al. Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients. Int J Cancer. 2004;111:934–939. doi: 10.1002/ijc.20366
   PubMed Web of Science ®Google Scholar
• Soria J-C, Morat L, Durdux C, et al. The molecular detection of circulating tumor cells in bladder cancer using telomerase activity. J Urol. 2002;167:352–356. doi: 10.1016/S0022-5347(05)65467-5
   PubMed Web of Science ®Google Scholar
• Leotsakos I, Dimopoulos P, Gkioka E, et al. Detection of circulating tumor cells in bladder cancer using multiplex PCR assays. Anticancer Res. 2014;34:7415–7424.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Wilson S, van Bokhoven A, et al. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology. 2011;78:863–867. doi: 10.1016/j.urology.2011.05.045
   PubMed Web of Science ®Google Scholar
• Rink M, Chun FK, Dahlem R, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol. 2012;61:810–817. doi: 10.1016/j.eururo.2012.01.017
   PubMed Web of Science ®Google Scholar
• Alva A, Friedlander T, Clark M, et al. Circulating tumor cells as potential biomarkers in bladder cancer. J Urol. 2015;194:790–798. doi: 10.1016/j.juro.2015.02.2951
   PubMed Web of Science ®Google Scholar
• Chalfin HJ, Kates M, van der Toom EE, et al. Characterization of urothelial cancer circulating tumor cells with a novel selection-free method. Urology. 2018;115:82–86. doi: 10.1016/j.urology.2018.01.036
   PubMed Web of Science ®Google Scholar
• Okegawa T, Hayashi K, Hara H, et al. Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer. Int J Urol. 2010;17:254–258. doi: 10.1111/j.1442-2042.2010.02454.x
   PubMed Web of Science ®Google Scholar
• Abrahamsson J, Aaltonen K, Engilbertsson H, et al. Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: association with tumor stage, lymph node metastases, FDG-PET findings, and survival. Urol Oncol. 2017;35:.e606.9–.e606.16. doi: 10.1016/j.urolonc.2017.05.021
   Web of Science ®Google Scholar
• Karl A, Tritschler S, Hofmann S, et al. Perioperative search for circulating tumor cells in patients undergoing radical cystectomy for bladder cancer. Eur J Med Res. 2009;14(11):487–490. doi: 10.1186/2047-783X-14-11-487
   PubMed Web of Science ®Google Scholar
• Engilbertsson H, Aaltonen KE, Björnsson S, et al. Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream. J Urol. 2015;193:53–57. doi: 10.1016/j.juro.2014.06.083
   PubMed Web of Science ®Google Scholar
• Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–6904. doi: 10.1158/1078-0432.CCR-04-0378
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–791. doi: 10.1056/NEJMoa040766
   PubMed Web of Science ®Google Scholar
• Busetto GM, Ferro M, Del Giudice F, et al. The prognostic role of Circulating Tumor Cells (CTC) in high-risk non-muscle-invasive bladder cancer. Clin Genitourin Cancer. 2017;15:e661–6. doi: 10.1016/j.clgc.2017.01.011
   PubMed Web of Science ®Google Scholar
• Gazzaniga P, de Berardinis E, Raimondi C, et al. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. Int J Cancer. 2014;135:1978–1982. doi: 10.1002/ijc.28830
   PubMed Web of Science ®Google Scholar
• Nicolazzo C, Busetto GM, Gradilone A, et al. Circulating tumor cells identify patients with super-high-risk non-muscle-invasive bladder cancer: updated outcome analysis of a prospective single-center trial. Oncology. 2019;24(5):612–616. doi: 10.1634/theoncologist.2018-0784
   Google Scholar
• Yang X, Lv J, Zhou Z, et al. Clinical application of circulating tumor cells and circulating endothelial cells in predicting bladder cancer prognosis and neoadjuvant chemosensitivity. Front Oncol. 2022;11:802188. doi: 10.3389/fonc.2021.802188
   PubMed Web of Science ®Google Scholar
• Morelli MB, Amantini C, Rossi de Vermandois JA, et al. Correlation between high PD-L1 and EMT/invasive genes expression and reduced recurrence-free survival in blood-circulating tumor cells from patients with non-muscle-invasive bladder cancer. Cancers (Basel). 2021;13(23):5989. doi: 10.3390/cancers13235989
   PubMed Web of Science ®Google Scholar
• Jiang H, Gu X, Zuo Z, et al. Prognostic value of circulating tumor cells in patients with bladder cancer: a meta-analysis. PLoS One. 2021;16(7):e0254433. doi: 10.1371/journal.pone.0254433
   PubMed Web of Science ®Google Scholar
• Amantini C, Maggi F, Rossi de Vermandois JA, et al. The prognostic value of the circulating tumor cell-based four mRNA scoring system: a new non-invasive setting for the management of bladder cancer. Cancers. 2022;14(13):3118. doi: 10.3390/cancers14133118
   PubMed Web of Science ®Google Scholar
• Guzzo TJ, McNeil BK, Bivalacqua TJ, et al. The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. Urol Oncol. 2012;30:44–48. doi: 10.1016/j.urolonc.2009.10.008
   PubMed Web of Science ®Google Scholar
• Winters B, James A, Lee J, et al. Chemotherapeutic effects on circulating tumor cells in bladder cancer. Int J Urol. 2015;22:612–613. doi: 10.1111/iju.12758
   PubMed Web of Science ®Google Scholar
• Pagliarulo V, Ancona P, Petitti T, et al. Detection and clinical significance of circulating tumor cells in patients undergoing radical cystectomy for urothelial bladder cancer. Clin Genitourin Cancer. 2017;15:455–462. doi: 10.1016/j.clgc.2016.11.005
   PubMed Web of Science ®Google Scholar
• A, Riethdorf S, Dahlem R, et al. A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy. Int J Cancer. 2017; 140:381–389. doi: 10.1002/ijc.30445
   PubMed Web of Science ®Google Scholar
• Cegan M, Kolostova K, Matkowski R, et al. In vitro culturing of viable circulating tumor cells of urinary bladder cancer. Int J Clin Exp Pathol. 2014;7:7164–7171.
   PubMed Web of Science ®Google Scholar
• Beije N, de Kruijff IE, de Jong JJ, et al. Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. ESMO Open. 2022;7(2):100416. doi: 10.1016/j.esmoop.2022.100416
   PubMed Web of Science ®Google Scholar
• de Kruijff IE, Beije N, Martens JWM, et al. Liquid biopsies to select patients for perioperative chemotherapy in muscle-invasive bladder cancer: a systematic review. Eur Urol Oncol. 2021;4(2):204–214. doi: 10.1016/j.euo.2020.01.003
   PubMed Web of Science ®Google Scholar
• Carrasco R, Ingelmo-Torres M, Gómez A, et al. Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer. World J Urol. 2022;40(8):2033–2039. doi: 10.1007/s00345-022-04061-9
   PubMed Web of Science ®Google Scholar
• Nicolazzo C, Busetto GM, Del Giudice F, et al. The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC). J Cancer Res Clin Oncol. 2017;143:1971–1976. doi: 10.1007/s00432-017-2449-8
   PubMed Web of Science ®Google Scholar
• Lima L, Neves M, Oliveira MI, et al. Sialyl-tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases. Urol Oncol. 2017;35:.e675.1–.e675.8. doi: 10.1016/j.urolonc.2017.08.012
   Web of Science ®Google Scholar
• Feber A, Dhami P, Dong L, et al. UroMark-a urinary biomarker assay for the detection of bladder cancer. Clin Epigenetics. 2017;9:8. doi: 10.1186/s13148-016-0303-5
   PubMed Web of Science ®Google Scholar
• Tan WS, Feber A, Dong L, et al. DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells. BMC Cancer. 2017;17:767. doi: 10.1186/s12885-017-3758-7
   PubMed Web of Science ®Google Scholar
• Jeannot E, Becette V, Campitelli M, et al. Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus‐associated invasive carcinoma. J Pathol Clin Res. 2016;2:201–209. doi: 10.1002/cjp2.47
   PubMedGoogle Scholar
• Mandel P, Metais P. [Nuclear acids in human blood plasma]. C R Seances Soc Biol Fil. 1948;142(3–4):241–243.
   PubMedGoogle Scholar
• Vandekerkhove G, Todenhöfer T, Annala M, et al. Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer. Clin Cancer Res. 2017;23:6487–6497. doi: 10.1158/1078-0432.CCR-17-1140
   PubMed Web of Science ®Google Scholar
• Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346ra92. doi: 10.1126/scitranslmed.aaf6219
   PubMed Web of Science ®Google Scholar
• Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7:302ra133. doi: 10.1126/scitranslmed.aab0021
   PubMed Web of Science ®Google Scholar
• Olsson E, Winter C, George A, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015;7:1034–1047. doi: 10.15252/emmm.201404913
   PubMed Web of Science ®Google Scholar
• Casadio V, Calistri D, Tebaldi M, et al. Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data. Urol Oncol. 2013;31:1744–1750. doi: 10.1016/j.urolonc.2012.07.013
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Alix-Panabières C, Müller I, et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res. 2009;15:1032–1038. doi: 10.1158/1078-0432.CCR-08-1910
   PubMed Web of Science ®Google Scholar
• Salvi S, Gurioli G, Martignano F, et al. Urine cell-free DNA integrity analysis for early detection of prostate cancer patients. Dis Markers. 2015;2015:574120. doi: 10.1155/2015/574120
   PubMed Web of Science ®Google Scholar
• Kim Y-H, Yan C, Lee I-S, et al. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer. Investig Clin Urol. 2016;57:106–112. doi: 10.4111/icu.2016.57.2.106
   PubMed Web of Science ®Google Scholar
• Casadio V, Salvi S, Martignano F, et al. Cell-free DNA integrity analysis in urine samples. J Vis Exp. 2017. doi: 10.3791/55049-v
   Web of Science ®Google Scholar
• Ghanjati F, Beermann A, Hermanns T, et al. Unreserved application of epigenetic methods to define differences of DNA methylation between urinary cellular and cell-free DNA. Cancer Biomark. 2014;14:295–302. doi: 10.3233/CBM-140407
   PubMed Web of Science ®Google Scholar
• Brisuda A, Pazourkova E, Soukup V, et al. Urinary cell-free DNA quantification as non-invasive biomarker in patients with bladder cancer. Urol Int. 2016;96:25–31. doi: 10.1159/000438828
   PubMed Web of Science ®Google Scholar
• Togneri FS, Ward DG, Foster JM, et al. Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. Eur J Hum Genet. 2016;24:1167–1174. doi: 10.1038/ejhg.2015.281
   PubMed Web of Science ®Google Scholar
• Szarvas T, Kovalszky I, Bedi K, et al. Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment. Oncol Rep. 2007;18:405–409. doi: 10.3892/or.18.2.405
   PubMed Web of Science ®Google Scholar
• de Almeida EFP, Abdalla TE, Arrym TP, et al. Plasma and urine DNA levels are related to microscopic hematuria in patients with bladder urothelial carcinoma. Clin Biochem. 2016;49:1274–1277. doi: 10.1016/j.clinbiochem.2016.08.021
   PubMed Web of Science ®Google Scholar
• Zancan M, Galdi F, Di Tonno F, et al. Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis. Int J Biol Markers. 2009;24(3):147–155. doi: 10.1177/172460080902400304
   PubMed Web of Science ®Google Scholar
• Christensen E, Birkenkamp-Demtröder K, Nordentoft I, et al. Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer. Eur Urol. 2017;71:961–969. doi: 10.1016/j.eururo.2016.12.016
   PubMed Web of Science ®Google Scholar
• Tse RT, Zhao H, Wong CY, et al. Urinary cell-free DNA in bladder cancer detection. Diagnostics. 2021;11(2):306. doi: 10.3390/diagnostics11020306
   Web of Science ®Google Scholar
• Zhang R, Zang J, Xie F, et al. Urinary molecular pathology for patients with newly diagnosed urothelial bladder cancer. J Urol. 2021 Oct;206(4):873–884. doi: 10.1097/JU.0000000000001878
   PubMedGoogle Scholar
• Chauhan PS, Chen K, Babbra RK, et al. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: a cohort study. PLOS Med. 2021 Aug 31;18(8): e1003732. Erratum in: PLoS Med. 2021;18(12):e1003876. doi: 10.1371/journal.pmed.1003732.
   PubMed Web of Science ®Google Scholar
• Dudley JC, Schroers-Martin J, Lazzareschi DV, et al. Detection and surveillance of bladder cancer using urine tumor DNA. Cancer Discov. 2019;9(4):500–509. doi: 10.1158/2159-8290.CD-18-0825
   PubMed Web of Science ®Google Scholar
• Ellinger J, Bastian PJ, Ellinger N, et al. Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. Cancer Lett. 2008;264:274–280. doi: 10.1016/j.canlet.2008.01.038
   PubMed Web of Science ®Google Scholar
• Christensen E, Nordentoft I, Vang S, et al. Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients. Sci Rep. 2018;8:1917. doi: 10.1038/s41598-018-20282-8
   PubMed Web of Science ®Google Scholar
• Christensen E, Birkenkamp-Demtröder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019;37:1547–1557. doi: 10.1200/JCO.18.02052
   PubMed Web of Science ®Google Scholar
• Ellinger J, Müller DC, Müller SC, et al. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. Urol Oncol. 2012;30:509–515. doi: 10.1016/j.urolonc.2010.03.004
   PubMed Web of Science ®Google Scholar
• Hauser S, Kogej M, Fechner G, et al. Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study. Anticancer Res. 2013;33:779–784.
   PubMed Web of Science ®Google Scholar
• Hauser S, Kogej M, Fechner G, et al. Cell-free serum DNA in patients with bladder cancer: results of a prospective multicenter study. Anticancer Res. 2012;32:3119–3124.
   PubMed Web of Science ®Google Scholar
• Soave A, Chun F-H, Hillebrand T, et al. Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. Oncotarget. 2017;8:56398–56407. doi: 10.18632/oncotarget.17657
   PubMedGoogle Scholar
• Birkenkamp-Demtröder K, Christensen E, Nordentoft I, et al. Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. Eur Urol. 2018;73(4):535–540. doi: 10.1016/j.eururo.2017.09.011
   PubMed Web of Science ®Google Scholar
• Vandekerkhove G, Lavoie JM, Annala M, et al. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun. 2021;12(1):184. doi: 10.1038/s41467-020-20493-6
   PubMed Web of Science ®Google Scholar
• Grunewald CM, Niegisch G, Albers P. Using circulating tumor DNA to guide adjuvant therapy in bladder cancer: iMvigor010 and iMvigor011. Eur Urol Focus. 2022;8(3):S2405-4569(22)00078–5. doi: 10.1016/j.euf.2022.04.001
   Google Scholar
• Fenner A. Using ctDNA to guide immunotherapy for urothelial cancer. Nat Rev Urol. 2021 Aug;18(8):443. doi: 10.1038/s41585-021-00503-y
   PubMed Web of Science ®Google Scholar
• Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021 Jul;595(7867):432–437. doi: 10.1038/s41586-021-03642-9
   PubMed Web of Science ®Google Scholar
• Szabados B, Kockx M, Assaf ZJ, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol. 2022;82(2):S212–222. doi: 10.1016/j.eururo.2022.04.013
   PubMed Web of Science ®Google Scholar
• Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol. 2010;28:655–661. doi: 10.1016/j.urolonc.2009.01.027
   PubMed Web of Science ®Google Scholar
• Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56:1733–1741. doi: 10.1373/clinchem.2010.147405
   PubMed Web of Science ®Google Scholar
• Mlcochova H, Hezova R, Stanik M, et al. Urine microRnas as potential noninvasive biomarkers in urologic cancers. Urol Oncol. 2014;32:41.e1–9. doi: 10.1016/j.urolonc.2013.04.011
   PubMed Web of Science ®Google Scholar
• Segersten U, Spector Y, Goren Y, et al. The role of microRNA profiling in prognosticating progression in ta and T1 urinary bladder cancer. Urol Oncol. 2014;32:613–618. doi: 10.1016/j.urolonc.2013.11.001
   PubMed Web of Science ®Google Scholar
• Pignot G, Cizeron-Clairac G, Vacher S, et al. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer. 2013;132:2479–2491. doi: 10.1002/ijc.27949
   PubMed Web of Science ®Google Scholar
• Mengual L, Lozano JJ, Ingelmo-Torres M, et al. Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int J Cancer. 2013;133:2631–2641. doi: 10.1002/ijc.28274
   PubMed Web of Science ®Google Scholar
• Zhang D-Z, Lau K-M, Chan ESY, et al. Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer. PLoS One. 2014;9:e100793. doi: 10.1371/journal.pone.0100793
   PubMed Web of Science ®Google Scholar
• Yamada Y, Enokida H, Kojima S, et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 2011;102:522–529. doi: 10.1111/j.1349-7006.2010.01816.x
   PubMed Web of Science ®Google Scholar
• Malentacchi F, Vinci S, Melina AD, et al. Urinary carbonic anhydrase IX splicing messenger RNA variants in urogenital cancers. Urol Oncol. 2016;34:.e292.9–.e292.16. doi: 10.1016/j.urolonc.2016.02.017
   Web of Science ®Google Scholar
• Valenberg FJPV, Hiar AM, Wallace E, et al. Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer. Eur Urol. 2019;75(5):853–860. doi: 10.1016/j.eururo.2018.11.055
   PubMed Web of Science ®Google Scholar
• Valenberg FJPV, Hiar AM, Wallace E, et al. Validation of an mRNA-based urine test for the detection of bladder cancer in patients with haematuria. Eur Urol Oncol. 2021 Feb;4(1):93–101. doi: 10.1016/j.euo.2020.09.001
   PubMed Web of Science ®Google Scholar
• Shkolyar E, Zhao Q, Mach KE, et al. Bladder cancer risk stratification using a urinary mRNA biomarker panel - a path towards cystoscopy triaging. Urol Oncol. 2021;39(8):.e497.9–.e497.15. doi: 10.1016/j.urolonc.2021.02.011
   Web of Science ®Google Scholar
• Bard MP, Hegmans JP, Hemmes A, et al. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol. 2004;31:114–121. doi: 10.1165/rcmb.2003-0238OC
   PubMed Web of Science ®Google Scholar
• Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110:13–21. doi: 10.1016/j.ygyno.2008.04.033
   PubMed Web of Science ®Google Scholar
• Nilsson J, Skog J, Nordstrand A, et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer. 2009;100:1603–1607. doi: 10.1038/sj.bjc.6605058
   PubMed Web of Science ®Google Scholar
• Welton JL, Khanna S, Giles PJ, et al. Proteomics analysis of bladder cancer exosomes. Mol & Cell Proteomics. 2010;9:1324–1338. doi: 10.1074/mcp.M000063-MCP201
   PubMed Web of Science ®Google Scholar
• Liang L-G, Kong M-Q, Zhou S, et al. An integrated double-filtration microfluidic device for isolation, enrichment and quantification of urinary extracellular vesicles for detection of bladder cancer. Sci Rep. 2017;7:46224. doi: 10.1038/srep46224
   PubMed Web of Science ®Google Scholar
• Armstrong DA, Green BB, Seigne JD, et al. MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer. Mol Cancer. 2015;14:194. doi: 10.1186/s12943-015-0466-2
   PubMed Web of Science ®Google Scholar
• Geng H, Zhou Q, Guo W, et al. Exosomes in bladder cancer: novel biomarkers and targets. J Zhejiang Univ Sci B. 2021;22(5):341–347.
   PubMed Web of Science ®Google Scholar
• Patel S, Ahmed S. Emerging field of metabolomics: big promise for cancer biomarker identification and drug discovery. J Pharm Biomed Anal. 2015;107:63–74. doi: 10.1016/j.jpba.2014.12.020
   PubMed Web of Science ®Google Scholar
• Loras A, Martínez-Bisbal MC, Quintás G, et al. Urinary metabolic signatures detect recurrences in non-muscle invasive bladder cancer. Cancers (Basel). 2019;11(7):914. doi: 10.3390/cancers11070914
   PubMed Web of Science ®Google Scholar
• Wang R, Kang H, Zhang X, et al. Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS. BMC Cancer. 2022;22(1):214. doi: 10.1186/s12885-022-09318-5
   PubMed Web of Science ®Google Scholar
• Jacyna J, Kordalewska M, Artymowicz M, et al. Pre- and post-resection urine metabolic profiles of bladder cancer patients: results of preliminary studies on time series metabolomics analysis. Cancers (Basel). 2022;14(5):1210. doi: 10.3390/cancers14051210
   PubMed Web of Science ®Google Scholar
• Zhuang J, Yang X, Zheng Q, et al. Metabolic profiling of bladder cancer patients’ serum reveals their sensitivity to neoadjuvant chemotherapy. Metabolites. 2022;12(6):558. doi: 10.3390/metabo12060558
   PubMed Web of Science ®Google Scholar
• Rouprêt M, Yates DR, Comperat E, et al. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol. 2008;54:1226–1236. doi: 10.1016/j.eururo.2008.08.008
   PubMed Web of Science ®Google Scholar
• Shishido SN, Ghoreifi A, Sayeed S, et al. Liquid biopsy landscape in patients with primary upper tract urothelial carcinoma. Cancers (Basel). 2022;14(12):3007. doi: 10.3390/cancers14123007
   PubMed Web of Science ®Google Scholar
• Xu Y, Ma X, Ai X, et al. A urine-based liquid biopsy method for detection of upper tract urinary carcinoma. Front Oncol. 2021;10:597486. doi: 10.3389/fonc.2020.597486
   PubMed Web of Science ®Google Scholar
• Nakano K, Koh Y, Yamamichi G, et al. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma. Cancer Sci. 2022;113(5):1830–1842. doi: 10.1111/cas.15334
   PubMed Web of Science ®Google Scholar